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ABSTRACT 
Introduction and background: In type 1 diabetic patients good glycaemic control is 
associated with complication reduction. Nevertheless a minority of patients, also treated with 
insulin pumps and continuous glucose monitoring (SAP therapy) achieve a satisfactory 
metabolic control. Several researchers are developing automatic systems, called  artificial 
pancreas (AP) or Closed Loop Control (CLC). This system are composed by an insulin pump, 
a continuous glucose monitoring device and a control algorithm which modifies insulin 
infusion from data derived by continuous glucose monitoring. Several AP models exist, 
composed by different insulin pumps, different continuous glucose monitoring system and by 
different control algorithms that determine the precision of glucose control.   
Method: we evaluated our AP model efficacy and safety at patients home compared to SAP 
therapy. In our AP model, the Algorithm is installed in a smartphone (DiAS, Diabetes 
Assistant) that communicate with pump and CGM thought blue tooth connection. We 
developed 5 studies that tested the system in free life condition, first during evening and 
night, than for 24 hours and for longer period (6 months). We finally evaluated this system in 
pediatric population.   
Results: In a randomized cross over study of 2 month AP use during evening and 
night vs SAP therapy, system usage improved time in target (70-180 mg/dl) from 58.1% to 
66.7%  ( P < 0.0001), reduce mean glucose concentration (162 mg/dl vs 167 mg/dl, 
P=0.0053)  and time spent in hypoglycemia (<70 mg/dl) from 3.0% to 1.7% (P < 0.0001) and 
lead to reduction in HbA1c values. Extension of this study for a month using AP 24 
hours/day demonstrated an improvement of time in target vs SAP (64.7 ± 7.6% vs. 59.7 ± 
9.6%, P = 0.01), reduction of time below the target (1.9 ± 1.1% vs. 3.2 ± 1.8%, P = 0.001). 
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A third trial evaluated a different algorithm for 2 weeks during overnight e for 2 
weeks for 24 hours, comparing these period with 2 weeks of SAP therapy. In overnight 
period AP improved glucose metric vs SAP: time spent in hypoglycaemia dropped from 3.0% 
to 1.1% (P < 0.001), time in target  increased from 61% to 75% (P < 0.001) , time spent 
above 180 mg/dl dropped from 37% to 24% (P < 0.001), the mean glucose concentration 
dropped from 163 to 150 mg/dL (P = 0.002). Similarly, metrics of glucose control in the 24-
hour AP usage vs SAP demonstrated reduction of the time below target from 4.1% to 1.7% (P 
< 0.001), increase of time in target from 65% to 73% (P < 0.001), decrease of time above 
target from 32% to 25% (P = 0.001). Comparing the overnight and 24 hours CLC, a reduction 
in time spent in hypoglycaemia was observed when AP was used for 24 hours. A subgroup of 
patients extended AP use for other 5 months, confirming AP efficacy (time in target:77% vs. 
66%, P<0.001, time in hypoglycaemia: 4.1% vs 1.3%, P < 0.001, time above target 31% vs 
22%, P = 0.01). Finally we tested the system in paediatric population, enrolling in a summer 
camp 30 subject 5-9 years old. During the night AP reduced time in hypoglycaemia (P < 
0.002), with no difference in time in target. During 24 hours we observed reduction of  the 
time in hypoglycaemia, from 6.7% to 2.0% (P < 0.001), but an increase of  mean glucose 
(147 mg/dL vs. 169 mg/dL, P < 0.001) and a decrease of time spent in target  (63.1% vs. 
56.8%, P = 0.022) 
Conclusions: These results demonstrated our model safety and efficacy. Some improvements 
are necessary to ameliorate glycaemiec control on pediatric population and during day time.  
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INTRODUCTION 
Type 1 diabetes (T1D) is an autoimmune disease characterized by pancreatic beta cell 
destruction with reduced or absent insulin production, leading to hyperglycaemia and 
abnormalities in lipid, protein and glycaemic metabolism. In normal subjects, insulin is 
produced continuously by beta cells to maintain regular basal metabolism and through peaks 
after meals to avoid postprandial hyperglycaemia.  
Insulin absence is quickly fatal and, until the discovery of insulin in 1921, diabetic 
subjects had no possibility of survival due to diabetic ketoacidosis. In the years several 
improvements in insulin therapy have been discovered. Human insulin, which has fewer 
collateral effects than animal insulin, was synthesized through molecular biology techniques 
in 1984. In the late 1990s, researchers created human insulin analogues
1
 with faster 
absorption from subcutaneous tissues to obtain postprandial glycaemic control, as well as 
analogues with slower absorption to ensure adequate insulin basal levels.  
It has been demonstrated that hyperglycaemia is associated with chronic disease 
complications such as retinopathy, nephropathy, neuropathy, and cardiovascular disease that 
reduce life expectancy and quality of life in diabetic patients
2
. Furthermore, several clinical 
trials have demonstrated that good glycaemic control is associated with reduction of 
complications and an increase in life expectancy
3-5
. These studies, underling the importance 
of glycaemic control avoiding hyperglycaemia, urge patients to control their glucose levels 
by administering several insulin injections per day. Metabolic control is evaluated through 
glycated haemoglobin (HbA1c), derived by non-enzymatic glycation due to plasma glucose 
haemoglobin exposition, which identifies the three-month average plasma glucose 
concentration
6
. HbA1c reduction reflects metabolic control improvements and is associated 
with the reduction of complications. The American Diabetes Association recommends a 
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HbA1c level below 7% (53 mmol/mol) for adults with T1D, which corresponds to a mean 
glucose value below 155 mg/dl (8.6 mmol/L)
7-8
. 
The most limiting factor for achieving good glycaemic levels is represented by 
hypoglycaemia, defined as glycaemic values lower than 70 mg/dl (<3.9 mmol/L), often due 
to excessive insulin administration. Hypoglycaemia impacts quality of life and leads to acute 
complications like seizures and coma, as well as and chronic issues
9-14
. Furthermore, fears of 
hypoglycaemia lead patients to accept higher glycaemic values, making it more difficult to 
achieve good metabolic control. 
Insulin is administrated through subcutaneous injections. Every day, diabetic patients 
have to administer several injection, one for each meals to avoid postprandial 
hyperglycaemia
16
, and one or more basal insulin injections to maintain basal insulin 
concentration. Alternatively, patients administer insulin through insulin pumps, small devices 
that continuously deliver basal insulin subcutaneously at pre-programmed rates. Insulin 
inserted into insulin pumps are fast insulin analogues that are administered in small boluses 
and guarantee a personalized basal concentration. Patients deliver prandial and corrective 
boluses of insulin, for example during a meal, through pump. Prandial boluses are calculated 
using insulin carbohydrates ratio
17
, defined as grams of carbohydrates metabolized by one 
unit of insulin. Correction boluses are calculated through a correction factor, defined as the 
reduction of glycaemia caused by one unit of insulin. Insulin pumps are composed of: 
 A subcutaneous needle that patients must change every two or three days, 
 A small catheter that connects the insulin cartridge to the needle, and 
 An insulin cartridge inserted into a device with a small piston that pushes insulin 
in the catheter at a pre-programmed infusion rate. 
Modern insulin pumps have different advanced functions to ameliorate problems with 
glucose control and improve patients’ quality of life. For example, all insulin pumps have an 
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integrated bolus advisor
18
 that simplifies decisions regarding meal and correction boluses on 
the basis of carbohydrate consumption and glycaemic values. Another function is temporary 
basal rate, which allows patients to increase or decrease the insulin basal rate for a 
determined period, for example during physical activity or illness. Extended boluses
19
 can 
improve postprandial control when patients consume a meal rich in protein or fat or in case of 
delayed gastric emptiness that leads to a latehyperglycaemia. 
It has been demonstrated that insulin pumps lead to better metabolic control with 
fewer hypoglycaemic events than multi-injection therapy and less complications incidence
20-
25
. For Example, Pickup demonstrated in a meta-analysis that insulin pumps lead to a 
reduction in HbA1c values of 0.5% over multi-injective therapy
21
. Furthermore, insulin 
pumps provide a reduction in insulin requirements and higher patient satisfaction
26-27
 
compared to multi-injection therapy, due to fewer injections, less pain, and increased 
portability.  
To avoid hypoglycaemia and achieve good glycaemic control, patients must check 
their blood glucose levels with a glucometer, a device that can report a glycaemic value from 
a blood drop obtain through the puncture of a finger in just a few seconds. These devices 
employ enzymes (like glucose oxidase or glucose reductase) that interact with glucose in the 
blood, subsequently determining electrochemical reactions that generate an electric current 
proportional to the amount of glucose in the blood that has reacted with the enzyme. Electric 
current is then transformed into a glycaemic value. Self-monitoring blood glucose control 
(SMBG) is important to determining the insulin bolus at meals and to evaluating glycaemic 
levels. It has been demonstrated that glucometer usage leads to improvements in HbA1c 
levels and a reduction in hypoglycaemic events
28
.  
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Continuous glucose monitoring (CGM) devices have been introduced in the last few 
decades. These systems measure continuously glucose level in subcutaneous interstitial fluid, 
providing patients with glucose values every few minutes. CGMs are composed of: 
 A small sensor applied in subcutaneous tissue by patients through an easy 
applicator. This sensor uses electrochemical technologies to transform glucose 
concentration into an electric impulse and then into a glycaemic value.  
 A transmitter that receives and analyses data from the sensor, improving accuracy 
with different software measurements, and then sends this data to a receiver. 
 A receiver that displays data to patients. Patients can see glucose values, trends 
arrows, and glycaemic values from the previous 24 hours.  
Though CGM systems are valid devices, there are some limitations in their use. First, 
there is a 15-minute lag between blood and subcutaneously measured glucose. Second, the 
accuracy of CGM systems can be poor, especially in the hypoglycaemic range. Third, CGM 
systems need to be calibrated at least twice a day through finger-stick glucose measurements. 
However, any therapeutic decision (such as hypo/hyperglycaemia corrections or the size of 
insulin boluses before meals) should be based on the finger-stick glycaemic value instead of 
CGM values. Currently available evidence shows that CGM helps lower HbA1c levels 
without increasing the incidence of severe hypoglycaemic episodes in patients with T1D
29-
32
.Nowadays, the gold standard in T1D therapy is the association between insulin pumps and 
continuous glucose monitoring: this associated therapy is called sensor augmented pump 
(SAP) therapy
33
. With SAP therapy, patients can modify insulin doses administered through 
insulin pumps on the basis of glucose values registered by the glucose sensor and measured 
through the glucometer. Nevertheless, patients with apparently good metabolic control, as 
demonstrated by HbA1c values, spend several hours per day out of the optimal glycaemic 
range, defined as glycaemic values from 70 to 180 mg/dl (3.9-10.0 mmol/l)
34
.  
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Artificial Pancreas 
 
In the last few years, a new technology called the artificial pancreas (AP), or closed 
loop control (CLC), has been developed to optimize glycaemic control
35
. As shown in Fig. 1, 
the AP uses a mathematical control algorithm that automatically modifies insulin infusion 
from values obtained by the CMG. Different approaches are currently under investigation, 
including systems using only insulin infusion and systems that combine insulin infusion with 
glucagon infusion.  
 
 
Fig 1: Artificial pancreas model 
 
 
Technology has played an important role in the lives of T1D patients, as demonstrated 
by progressive improvements in CGM devices and precision in insulin pumps. From the end 
of 1970, with the introduction of the insulin pump, researchers have tried automatic insulin 
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infusion methods using different approaches
36-42
. Partial automation has already developed 
and been commercialized to help prevent hypoglycaemia. A system called low glucose 
suspend (LGS) has been available from some years. This system suspends insulin infusion 
when sensors reveal low glucose values and protects patients from severe hypoglycaemia
43
. 
Another step in automatic insulin infusion is the predictive low glucose suspend (PLGS) 
system, which suspends insulin infusion when the sensor predicts a risk of hypoglycaemia 
before it occurs and reducing the risk of glycaemia below the threshold
44
.  
AP development should guarantee complete automation also for hyperglycaemic 
control. Current APs are composed of a CGM device, an insulin pump (a glucagon pump 
when applicable), and a control algorithm. The control algorithm is the brain of the system 
and different algorithms are used by different groups to drive insulin infusion. So far, three 
different control algorithms have been used: model predictive control (MPC), proportional-
integral derivative (PID) control, and fuzzy logic. 
Control Algorithms 
MPC 
The MPC algorithm
45-46
 uses mathematical models to calculate future blood glucose 
levels on the basis of present glucose levels, glucose trends, and the insulin already 
administered. MPC administers insulin on the basis of glucose prediction and can modify its 
strategy every few minutes when new glucose values and a new future glucose prediction 
become available.  
PID  
The PID algorithm
47
 continuously adjusts insulin infusion rates by considering 
deviations of the patient’s blood glucose level from ideal levels (the proportional 
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component), the area under the curve between ambient and target blood glucose (the integral 
component), and the rate of change of the patient’s blood glucose (the derivative component). 
The notable difference with MPC is that the MPC algorithm can be considered proactive, 
which this algorithm is just reactive. 
Fuzzy Logic 
This algorithm tries to imitate medical decisions
48
; it takes into account an individual 
patient’s treatment characteristics and imitates medical decision-making with respect to 
glucose control, modulating insulin delivery on the basis of approximate rules derived from 
empirical knowledge acquired by diabetes practionners 
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Our Artificial Pancreas Model 
In the last decade, a University of Padova group composed of a clinical and 
engineering team, cooperating with several European and American research centres, has 
developed an AP model based on the MPC control algorithm. The MPC approach is powered 
by a modular architecture composed of independent but compatible modules, each 
performing a specific control
49-50
. It includes three interacting control modules: a safety 
module that prevents hypoglycaemia
51
, a range control module responsible for insulin 
corrections and glycaemia optimization
49
, and an insulin-on-board module preventing insulin 
stacking
52
. This system is called the multi model predictive control (MMPC). 
The control algorithm uses patient parameters to choose better strategies to control 
glycaemic values. In fact, the system starts with the usual insulin basal rate, weight, total 
daily insulin, correction factor, and insulin carbohydrate ratio to optimize control.  
 
Preliminary Studies 
The algorithm was first tested using an in silico model, which has accelerated the 
progress of AP development. In 2008, the US Food and Drug Administration (FDA) accepted 
a simulator as a substitute to animal trials for the testing of CLC strategies. The simulator was 
based on a sophisticated model of glucose-insulin dynamics
53-54
, and included a virtual 
population of 300 subjects, created on the basis of real glycaemic values. Three age groups of 
virtual patients exist, including children, adolescents, and adults
55
. Simulation experiments 
now allow that CLC system to be tested in silico, prior to their use in clinical trials, in a rapid 
and cost-effective way.  
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After in silico testing, the AP was tested in inpatient clinical trials between 2008 and 
2011. The aim of these trials was to evaluate the efficacy and safety of the closed loop system 
previously tested in silico. In these early studies, insulin pump commands were entered 
manually by clinicians when it was considered safe for patients
56
. Most of these studies 
demonstrated the superiority of CLC over standard insulin pump therapy (continuous 
subcutaneous insulin infusion, CSII) or SAP therapy in terms of increased time within target 
glucose range, better overnight control and a reduced incidence of hypoglycaemia
57-58
. 
Automated communication between devices (CGM devices, insulin pumps, and control 
algorithms) was made possible with introduction of platform “Artificial Pancreas Software 
(APS)”, which led to automated data transfer59. First trial involving our Center was published 
in 2012. This study enrolled 38 patients and tested two different control algorithms
60
.  
The Diabetes Assistant (DiAs) and Outpatient Studies 
Results obtained through in silico and inpatient studies allowed researchers to test the 
system outside hospitals. These outpatient studies were conducted in a safe and convenient 
location, like a hotel, where the clinical team could meet together with patients. The 
transition to CLC testing in an outpatient setting began in 2011 with the introduction of the 
Diabetes Assistant (DiAs)
61-62
, our first wearable AP platform for outpatient settings, 
developed at the University of Virginia. In the wearable AP, the model control algorithm was 
uploaded to a smartphone that can communicate through a wireless Bluetooth connection to 
the CGM and the insulin pump. When equipped with a Bluetooth system, the DiAs can 
communicate with different CGMs and pumps. The DiAs can operate in four different 
modes:  
 CLC mode: the DiAs is connected to a pump and a sensor, and the algorithm is 
activated.  
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 Open loop (OL) mode: the pump and sensor are connected, but the algorithm is 
not active, so patients can see sensor data and the system delivers the normal basal 
rate, as with usual therapy.  
 Sensor only: the sensor is connected, but the pump is not. Patients can see sensor 
values and insulin is delivered directly by the pump with normal settings. 
 Safety mode: A variant of the CLC mode, the algorithm is activated to reduce 
insulin on the basis of glycaemia to mitigate the risk of hypoglycaemia, but can’t 
administer more insulin than usual. This mode is used to avoid hypoglycaemia 
when patients engage in potentially dangerous activities like driving. 
The patient interacts with the system through a touch-screen graphical user interface, 
as shown in Fig. 2, which allows real-time inputs like meal announcements, pre-meal 
capillary glucose levels, or self-administered hypoglycaemia treatment. It is a semi-automatic 
AP because patients have to manually input carbohydrate intake to obtain a meal bolus 
suggestion on the basis of glycaemic values and insulin infusion until that moment, which 
patients can then accept or modify.  
The platform is easy to use and allows outpatient studies that were not possible with 
systems composed of a personal computer and wired connections, used in an inpatient 
setting. Furthermore, a 3G Smartphone connection enables the sending of data to a remote, 
secure website where the clinical team can control glycaemic trends and system function.   
In October 2011, DiAs was used in two pilot trials of portable outpatient AP 
conducted simultaneously in Padova and Montpellier
66
. These two-day pilot trials found that 
the DiAs is a feasible prototype for a portable outpatient CLC system and that enabled a 
subsequent multi-site feasibility study of ambulatory AP. 
15 
 
 
Fig.2 : DiAs interface. It’s possible observe connection status between Dias and insulin pump or 
CGM, glycemic values registered by CGM and hypoglycemia and hyperglycemia risk through traffic 
light. Patient could insert glycemic values measured through glucometer, carbohydrate intake at meal, 
eventual hypoglycaemia treatment.  
 
After this feasibility study, several safety and efficacy studies with the DiAs were 
conducted from 2011 to 2014. In these studies, the DiAs was used in several conditions, 
during physical activity, and with adolescents, demonstrating its efficacy and safety 
compared to sensor augmented pump therapy
64-65
.  
For example, our group was involved in a trial in a hotel setting where AP was used 
overnight, while patients returned home and managed their therapy with pump and sensor 
during the daytime. This trial of 44 patients demonstrated that using CLC from 23:00 to 7:00 
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significantly improved time in target (70-180 mg/dL, 3.9-10 mmol/L) vs. SAP during the 
night (85.7% vs. 67.6%, P < 0.001) but also over 24 hours (78.3% vs. 71.4%, P = 0.003). 
Time spent in hypoglycaemia (<70 mg/dl, <3.9 mmol/L) decreased with CLC during the 
overnight period from 3.2% to 0.9% (P < 0.001) and during 24 hours from 4.3% to 2.5% (P = 
0.002). The mean glucose at 07:00 was also improved with CLC (124 vs. 145 mg/dL; 6.8 vs. 
8.0 mmol/L, P < 0.001)
66
.  
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Monitoring Service 
The possibility of controlling glycaemic trends and CLC function has been 
fundamental to developing trials of AP use in patients’ homes. In fact, clinical teams must be 
able to check DiAs activity at any time, and call the patient if necessary in case of system 
malfunction or persistent hypoglycaemia. Remote website control was necessary in the first 
trials for safety and to obtain approval from ethical committees and regulatory boards. With 
this system shown in Fig. 3, clinicians can always check glucose values, hypo- and 
hyperglycaemia risk (traffic lights), insulin administered by the system, insulin administered 
by patients through boluses, DiAs mode activity, and carbohydrate intake
67
.   
 
Fig 3: screenshot of web monitoring site. Green bars are insulin basal rate administered by system, 
blue circles are CGM values.  
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AIM 
The aim of this thesis was to describe ourAP use at patients’ homes and the results of 
studies conducted from 2014-2017. As shown in Fig. 4, the AP system used in these trials 
was composed of DiAs system using a Dexcom G4 as the CGM with Accu-Chek Spirit 
Combo insulin pumps. 
 
Fig 4: Our artificial pancreas model including DiAs, insulin pump (Accuchek Spirit Combo®, Roche 
Diabetes Care) and CGM (Dexcom G4®, Dexcom) inserted in relay box to allow Bluetooth 
communication between receiver and DiAs 
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Dexcom G4  
As the CGM for these studies, the Dexcom G4,  developed by DexCom (San Diego, 
CA), was used. As shown in Fig. 5 the system is composed of four different parts: 
 A small electrochemical sensor placed just under the skin, 
 A one-use injector, 
 A transmitter connected to the sensor, and 
 A monitor that receives sensor signals and provides real-time results. 
The 13mm long sensor probe is positioned at a 45° angle under the skin. It is  placed 
with the help of an inserter and can  be used for up to seven days. Using amperometry, the 
sensor uses a working electrode coated with a sensing element (Wired Enzyme) that converts 
glucose concentration to electrical current. The transmitter snaps into the sensor and sends 
glucose information through a secured wireless connection to the receiver every five minutes. 
The receiver has a large screen that displays glucose values and glucose trends, as well as 
customizable alarms that can inform patients about potential hypo- or hyperglycaemia. The 
receiver can store up to 30 days of data. 
 
 
 
 
 
 
Fig 5: Dexcom G4Continuos Glucose Monitoring system: on the right there is sensor with its 
applicator, on the left the transmitter and the receiver where patient could visualize glycemic 
values.  
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Once installed, the system needs a two-hour warm-up period of initialization before it 
can provide continuous glucose data. According to the manufacturer’s recommendations, the 
sensor must be calibrated two hours after insertion, and at least twice a day thereafter. 
Calibration values must be manually entered by the patient when performing a capillary 
glucose control with the glucometer. The Dexcom G4 is not equipped with a Bluetooth 
connection, so the Dexcom receiver was linked to a dedicated Bluetooth-USB hub, called a 
relay box, to allow glycaemic data transmission from the CGM to the DiAs. 
Accu-Chek
®
 Spirit Combo 
The Accu-Chek
®
 Spirit Combo Insulin Pump is a fully integrated insulin delivery 
system developed by Roche (Switzerland). As shown in Fig. 6, the system includes two 
components: 
 An external insulin pump, which can be connected to a subcutaneous catheter. 
Pump contains an insulin reservoir with a capacity of 315U . The basal rate can be 
reduced to a minimum of 0.05 U/hour, delivering a bolus in 20 intervals over the 
course of the hour.  
 A glucometer, which patients can use to control their capillary blood glucose. This 
also includes an integrated a remote control that can communicate with the insulin 
pump and used to perform an insulin bolus. 
 
 
 
 
Fig 6: Accuchek Spirit Combo insulin pump. On the left the glucometer and on the right insulin 
pump. They are equipped with blue tooth connection possibility. 
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Bluetooth technology is embedded in the insulin pump, allowing data transfer either 
to the remote control or to an AP system. During AP use, a communication link is established 
between the insulin pump and the AP platform. 
The Accu-Chek glucometer was used as the reference study glucometer. 
This AP prototype was used in several studies, first during the night-time period, next 
for a 24-hour period, and then for progressively longer periods. Finally, it was tested on a 
paediatric population.  
The principal studies described in this thesis are:  
- 2 month evening and night closed loop glucose control in patients with type 1 
diabetes under free-living conditions: a randomized cross-over trial 
- Day and night closed loop glucose control in patients with type 1 diabetes under 
free-living conditions  
- Multinational Home Use of Closed-Loop Control Is Safe and Effective 
-  Feasibility of long term closed-loop control: a multicenter 6 month trial of 24/7 
automated insulin delivery 
-  Randomized Summer Camp Crossover Trial in 5- to 9-Year-Old Children: 
Outpatient Wearable Artificial Pancreas Is Feasible and Safe.  
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2 MONTH EVENING AND NIGHT CLOSED LOOP GLUCOSE CONTROL IN 
PATIENTS WITH TYPE 1 DIABETES UNDER FREE-LIVING CONDITIONS: A 
RANDOMISED CROSS-OVER TRIAL 
 
This trial
68
 was the first two-month randomized controlled crossover study that 
investigated evening and night period control with a closed loop system during truly free-
living conditions. It was a multi-centre trial involving the University of Padua, the University 
of Montpellier, and the University of Amsterdam. We used an MMPC control algorithm 
created by the University of Padua and Pavia
69
. This study evaluated the efficacy of CLC 
during the evening and night period, from before dinner to waking up, because night-time 
seems like the easiest period to improve glucose control because changes in meals and 
exercise predominantly occur during the daytime
70-71
. The use of the overnight CLC was 
extended at home with the addition of the evening period to increase CLC use and test the 
system during a meal, maximizing the time of glucose control that is possible at home 
because most high-risk activities—including strenuous sports and driving—are not done at 
home. During daytime, patients managed diabetes using SAP therapy.  
Methods 
The study was a randomized crossover study with patients either starting two months 
of AP using during evening and night period and SAP during daytime or two months using 
24 hours SAP therapy (open loop period, OL). During two study periods, patients were 
encouraged to maintain the same schedules, especially regarding physical activity.  
The main inclusion criteria were patients aged 18–69 years, with a diagnosis of T1D 
for at least six months according to the American Diabetes Association criteria, a BMI of less 
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than 35 kg/m², and a concentration of HbA1c between 7.5% and 10% (58–86 mmol/mol). All 
patients were experienced insulin pump users and trained in carbohydrate counting. To 
mitigate risk, patients with severe hypoglycaemia in the past year or ketoacidosis in the past 
six months were excluded. Patients were also excluded if they were pregnant or 
breastfeeding, used medication that substantially altered their glucose metabolism, had 
uncontrolled hypertension (resting >140/90 mm Hg), worked during the night or expected to 
be away from home for longer than 25% of the study duration, had no family or friends 
nearby, had a malignant disease, had an acute cardiovascular event during the previous year, 
had renal insufficiency (creatinine >150 μmol/L), had impairment of liver function (levels of 
liver enzymes more than twice the upper limit of normal), or had impaired cognitive or 
psychological abilities. During the trial, a monitoring website was active so that the clinical 
team could evaluate system functioning for patient safety when necessary.  
After a screening and two-week run-in period, patients were randomized into two 
groups and instructed either to use AP during the evening and night-time or to use SAP 
therapy 24 hours for eight weeks. The two periods were separated by a four-week washout in 
which patients used the study pump with or without CGM according to their pre-study 
treatment. HbA1c was measured at the beginning and end of each period (Fig. 7). The aim of 
the study was to evaluate time in target changes during AP use, and the secondary outcome 
was the evaluation of HbA1c changes between two periods.  
24 
 
 
Figure 7: study design. 17 patients started open loop period and 15 closed loop one. After 4 wash out 
weeks patients changed their treatment. 
 
Results 
Table 1 shows the characteristics of the 32 patients who completed this study. Data 
from the first two weeks of both arms were considered the training period and excluded from 
analysis.  
Characteristic Study Population (n=32) 
Age (years) 47 ± 11.2 
Sex (male) 18 (56%) 
BMI (Kg/m
2
) 25.1 ± 3.5 
HbA1c (%) 8.2 ± 0.6 
Diabetes duration (years) 28.6 ± 10.8 
Table1: baseline characteristic of 32 patients. Data are described as mean ± standard deviation or 
number (%) 
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CGM values were analysed over two study periods. During AP use, from 20.00 in the 
evening to 8:00 in the morning (Table 2), time in target (70-180 mg/dl, 3.9-10.0 mmol/L) was 
higher than in the two months when patients used OL (66.7% vs. 58.1%; P < 0.0001). Mean 
glucose concentration was also lower during the AP period than during the control period 
(162 vs 167 mg/dl, 9.0 mmol/L vs. 9.3 mmol/L, P = 0.0053). AP reduced time spent in 
hypoglycaemia (<70 mg/dl, <3.9 mmol/L) from 3.0% in the control period to 1.7% in the AP 
period (P < 0.0001).  
 
Evening and night period 
Metrics CLC period OL period P value 
Glucose concentration, mg/dl 162±14.4 167±14.4 0.0053 
Glucose standard deviation, mg/dl 55.8±10.8 61.2±10.8 <0.0001 
Time in target (70-180 mg/dl), % 66.7±10.1 58.1±9.4 <0.0001 
Time in tight target (80-140 mg/dl), % 37.7±9.1 31.2±6.0 <0.0001 
Time below target (< 70 mg/dl), %  1.7 (0.8-2.5) 3.0± (1.6-4.9) <0.0001 
Time above target (>180 mg/dl) % 31.6±9.9 38.5±9.7 <0.0001 
Hypoglycemic events/week, n 4.3±1.9 5.8±2.9 0.0068 
Insulin used, IU 16.2±7.0 18.4±8.7 0.0029 
Table 2: results during evening and night period, expressed as mean ± standard deviation, except for 
time below target expressed as median and 95% CI.  
 
Glycaemic values in the early morning were lower during the closed-loop period than 
during the control period (144 mg/dl vs. 160 mg/dl, 8.0 mmol/L vs. 8.9 mmol/L; P < 
0.0001;), with an increase in time in target from 65.9% to 85.9% (P < 0.0001). As shown in 
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Table 3, an improvement of glycaemic metrics was observed over a 24 hour period, even if 
CLC was only used overnight. Use of the AP during the evening and at night also led to a 
reduction in glucose variability during period use (standard deviation, SD 55.8 vs. 61.2 
mg/dl, 3.1 vs. 3.4 mmol/L, P < 0.0001), early morning (0600–0700 h, SD 41.4 vs. 55.8 
mg/dl, 2.3 vs. 3.1 mmol/L, P < 0.0001), and over 24 hours (SD 59.4 vs. 61.2 mg/dl, 3.3 L vs. 
3.4 mmol/L, P = 0.0009). It’s important to highlight that the decrease in mean HbA1c during 
the AP period was significantly greater than during the control period (–0.3% vs. –0.2%; P = 
0.047).  
24 hours, day and night 
Metrics CLC period OL period P value 
Glucose concentration, mg/dl 160.2 (154.8-165.6) 163.8(158.4-169.2 0.056 
Glucose standard deviation, mg/dl 59.4±9 61.2±9 0.0009 
Time in target (70-180 mg/dl), % 63.7 (60.4-70.1) 59.4 (56.7-64.3) <0.0001 
Time in tight target (80-140 mg/dl) 
% 
36.3±7.7 32.6±6.3 0.0002 
Time below target (< 70 mg/dl), % 2.6±1.4 3.6±2.0 0.0002 
Time above target (>180 mg/dl) % 33.5 (27.8-36.7) 36.4 (32.1-39.8) 0.0008 
Hypoglycemic events/week, n 5.7±2.5 6.3±2.4 0.15 
Insulin used, IU 36.7±11.7 43.2±16.3 <0.0001 
Table 3: results during 24 hours, expressed as mean ± standard deviation, or median (95% CI).  
 
During the AP period, mean insulin needs were lower than in the control period, 
during the evening-night period (16.2 IU vs. 18.4 IU, P = 0.0029), and over 24 hours (36.7 IU 
vs. 43.2 IU, P < 0.0001). 
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The telemonitoring website worked correctly, but clinician intervention was not 
necessary.  
At the beginning and end of both periods, patients completed two questionnaire: the 
Diabetes Treatments Satisfaction Questionnaire (DTSQ)
72
 that analyses satisfaction for 
quality of therapy in diabetic patients and the Hypoglycaemia Fear Survey 2 (HFS2)
73
 that 
investigates patients behaviour in avoiding hypoglycaemic events. There were no differences 
in questionnaires before and after AP use and between the two periods. Patients also 
completed a specific AP acceptance questionnaire
74
 and 74% fully agreed with the statement 
“I would want to use an Artificial Pancreas for a prolonged period”, demonstrating the 
feasibility of the system in daily life. 
Conclusions 
This was the first trial conducted with this AP model in patients’ homes and the 
results were very encouraging; AP improves all glycaemic targets during the evening and 
night period and increased the time spent in target during the 24 hour period. It’s important to 
underline that this was the first trial conducted in free life conditions. Even though the AP 
was only used during the evening and night, for a median use of eight hours/day, and just for 
eight weeks, reduction of the time spent in hyperglycaemia and an increase of time spent in 
target led to a reduction in HbA1c, a metabolic parameter that usually reflects metabolic 
control over the previous three months. Use of the AP during dinner, and not just during the 
night, allowed the study to test the system during a period in which glycaemic control is more 
difficult to achieve. 
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DAY-AND-NIGHT CLOSED-LOOP GLUCOSE CONTROL IN PATIENTS WITH 
TYPE 1 DIABETES UNDER FREE-LIVING CONDITIONS: RESULTS OF A 
SINGLE-ARM 1-MONTH EXPERIENCE COMPARED WITH A PREVIOUSLY 
REPORTED FEASIBILITY STUDY OF EVENING AND NIGHT AT HOME 
Results obtained in the previous study lead to an extension period
75
 in which the AP 
was used all day, always in free life conditions.  
Methods 
As shown in Table 4, 20 of 32 patients enrolled in the previous study agreed to 
continue the study by using the AP 24 hours a day in this single arm study. The study used 
the same inclusion criteria, monitoring website, and technology as the previous study. For 
safety reasons, patients were asked to avoid dangerous activity like driving with the AP, so 
they switched off the DiAs during these activities. 
 
Characteristic Study Population (n=20) 
Age (years) 46.3 ± 11.0 
Sex (male) 9 (45%) 
BMI (Kg/m
2
) 24.9 ± 3.5 
HbA1c (%) 8.2 ± 0.7 
Diabetes duration (years) 28.9 ± 12.8 
Table 4: baseline characteristic of 20 patients. Data are described as mean ± standard deviation or 
number (%) 
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Results 
All patients completed the four-week extension study. Data derived from the CGM 
were analysed and compared with data during the OL period and the evening and night AP 
control period of previous study. As shown in Tables 5 and 6, using AP for the 24 hour 
period improved the percentage of time in target range over SAP use alone (64.7 ± 7.6% vs. 
59.7 ± 9.6%, P = 0.01), and close to significance with the use of AP during evening and night 
(P = 0.06). Significant improvements came from reducing the percentage of time below the 
target range using 24 hour CLC versus SAP (1.9 ± 1.1% vs. 3.2 ± 1.8%, P = 0.001), but no 
difference was found between the use of AP for 24 hours or for evening and night (P = 0.79). 
 
24 hours, day and night 
Metrics (20 patients) 24h CLC period OL period P value 
Glucose concentration, mg/dl 160.2 (153.0-169.2) 
162.0(156.6-
171.0) 
0.51 
Glucose standard deviation, mg/dl 55.8±9 59.4±10.8 0.049 
Time in target (70-180 mg/dl), % 64.7±7.6 59.7±9.6 0.01 
Time in tight target (80-140 mg/dl), 
% 
35.4±5.8 32.4±7.5 0.16 
Time below target (< 70 mg/dl), %  1.9±1.1 3.2±1.8 <0.001 
Time above target (>180 mg/dl) % 33.3±7.3 37.0±10.2 0.10 
Hypoglycemic events/week, n 5.0±2.4 6.4±3.1 0.03 
Insulin used, IU 40.3±15.2 42.3±15.5 0.34 
Table 5: results during 24 hours, expressed as mean ± standard deviation, or median (25
th
 -75
th
 
percentile).  
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24 hours, day and night 
Metrics (20 patients) 24h CLC period 
Evening and 
night CLC period 
P value 
Glucose concentration, mg/dl 160.2 (153.0-169.2) 
160.2(154.8-
171.0) 
0.71 
Glucose standard deviation, mg/dl 55.8±9 59.4±10.8 0.23 
Time in target (70-180 mg/dl), % 64.7±7.6 63.6±9.9 0.79 
Time in tight target (80-140 mg/dl), 
% 
35.4±5.8 35.5±9.0 1.00 
Time below target (< 70 mg/dl), %  1.9±1.1 2.1±1.3 0.74 
Time above target (>180 mg/dl) % 33.3±7.3 34.2±10.0 0.87 
Hypoglycemic events/week, n 5.0±2.4 4.9±2.6 0.98 
Insulin used, IU 40.3±15.2 36.6±11.6 0.02 
Table 6: 24h CLC control vs Evening and night CLC results during 24 hours, expressed as mean ± 
standard deviation, or median (25
th
 -75
th
 percentile).  
 
During evening and night (2000–0800), the percentage of time in the target range and 
below the target range were significantly improved during both AP periods versus SAP. 
During daytime (0800–2000), as shown in tables 7 and 8, the percentage of time in the target 
range and the mean blood glucose levels showed no difference among the three treatments, 
but a trend toward improvement of the percentage of time in the target range was recorded 
with 24 hours AP usage versus SAP (64.9 ± 8.1 vs. 60.7 ± 10.3, P = 0.09). The percentage of 
time spent in hypoglycaemia when AP was used for 24 hours was significantly lower than 
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with SAP (2.3 ± 1.3% vs. 3.4 ± 2.2%, P = 0.01), but was not significantly different compared 
with AP used during the evening and night (2.3 ± 1.3% vs. 2.9 ± 1.9%, P = 0.25).  
 
Daytime (8:00-20:00) 
Metrics (20 patients) 24h CLC period SAP therapy P value 
Glucose concentration, mg/dl 162±9 163.8±18 0.38 
Glucose standard deviation, mg/dl 57.6±10.8 59.4±10.8 0.15 
Time in target (70-180 mg/dl), % 64.9±8.1 60.7±10.3 0.09 
Time in tight target (80-140 mg/dl), 
% 
35.6±6.5 33.4±8.8 0.46 
Time below target (< 70 mg/dl), %  2.3±1.3 3.4±2.2 0.01 
Time above target (>180 mg/dl) % 32.8±7.8 35.8±11.4 0.34 
Hypoglycemic events/week, n 3.3±1.8 3.9±2.3 0.34 
Insulin used, IU 19.3 (16.1-31-8) 22.9 (18.2-27.5) 0.71 
Table 7: results during daytime of 24 hours CLC vs SAP, expressed as mean ± standard deviation, or 
median (25
th
 -75
th
 percentile).  
Daytime (8:00-20:00) 
Metrics (20 patients) 24h CLC period 
Evening and 
night CLC period 
P value 
Glucose concentration, mg/dl 162±9 165.6±21.6 0.38 
Glucose standard deviation, mg/dl 57.6±10.8 61.2±12.6 0.003 
Time in target (70-180 mg/dl), % 64.9±8.1 61.2±11.7 0.15 
Time in tight target (80-140 mg/dl), 
% 
35.6±6.5 34.1±9.3 0.72 
32 
 
Time below target (< 70 mg/dl), %  2.3±1.3 2.9±1.9 0.25 
Time above target (>180 mg/dl) % 25.6±10.7 29.1±10.2 0.32 
Hypoglycemic events/week, n 3.3±1.8 3.4±1.9 0.94 
Insulin used, IU 19.3 (16.1-31-8) 18.5 (15.5-24.9) 0.74 
Table 8: results during daytime of 24 hours CLC vs Evening and night CLC, expressed as mean ± 
standard deviation, or median (25
th
 -75
th
 percentile).  
 
Although the percentage of time above the target range was similar between usage 
during AP periods and SAP, the percentage of time with glucose above 300 mg/dl (16.5 
mmol/L) was significantly lower when AP was used for 24 hours than AP usage in the 
evening and night period (P = 0.004). 
The SD of blood glucose during evening and night usage was significantly reduced 
with use of AP during the evening night or for 24 hours vs. SAP, but glucose SD during 
daytime was significantly reduced only when AP was used for 24 hours.  
Patients spent 80.4% in the closed loop during the 24-hour period, demonstrating a 
good but improvable connection system between devices, particularly during daytime when 
patients had work activities, with a CLC usage of 73.9% (70.7% in the morning, from 08:00 
to 12:00, and 75.5% in the afternoon, from 12:00 to 20:00). 
No serious adverse events occurred during the AP use for the 24-hour test, with no 
severe hypoglycaemic episodes and no hospitalization for ketoacidosis. 
Conclusions 
This trial was the first to compare the efficacy and safety of two AP approaches (24 
hour usage and evening and night usage) vs. SAP during several weeks in free-living 
conditions. It was also our first trial to measure AP use for 24 hours a day. Other groups 
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evaluated day and night efficacy of closed loop control versus SAP in a well-designed trial 
with good results in glycaemic control during the day. This study was not designed to 
evaluate day and night efficacy because it was an extension of a previous study, but the 
results were encouraging. In particular, AP usage during daytime reduced glucose variability, 
which is associated with chronic diabetes complications. It was not surprising that AP use 
during the night improved glycaemic control also in daytime, which was demonstrated in 
previous studies in outpatients setting
65
.  
Insulin dose with 24-hour AP usage was greater than evening and night AP usage, but 
not different from SAP therapy. It can be argued that AP used less insulin during the evening-
night control, but the 24-hour revealed that there was an increase in the insulin basal rate in 
the post-meal period to reduce hyperglycaemia and variability. 
Although glycaemic control with AP usage for 24 hours was better than with SAP 
therapy, the control algorithm had to be retuned to ameliorate daytime control compared to 
AP use in the night-time period. Nevertheless, it’s important to stress that in this first 24-hour 
usage of the AP model, there were no adverse events and patient acceptation of the device 
was great. There were some connection problems between the pump-CGM and DiAs that 
could further challenge the limited expected benefits of AP on glucose control during the 
daytime, so a more integrated system with fewer disconnection problems could increase the 
efficacy of the system. 
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MULTINATIONAL HOME USE OF CLOSED-LOOP CONTROL IS SAFE AND 
EFFECTIVE 
Conducted between 2015 and 2016, this trial
76
 was an international trial involving 
patients form our centre and from three different centre in the US (the University of Virginia, 
Stanford University, and the William Sansum Diabetes Center), Europe (the University of 
Montpellier,) and Israel (the Institute of Endocrinology and Diabetes, Tel Aviv). The aim of 
this study was to evaluate the efficacy of the wearable, wireless AP system, DiAs, on glucose 
control at home, in an overnight period and during a 24-hour usage period. In contrast from 
previous studies, in this trial, the algorithm used in the DiAs was not the Padova-Pavia 
algorithm, but the Unified Safety System (USS), an algorithm developed at the University of 
Virginia. It is a multi-modular MPC algorithm, but with some differences. In fact, while the 
University of Padua-Pavia algorithm can modulate only the basal infusion rate, the USS can 
also administer correction boluses if glycaemia is rising too fast.  
Methods 
Thirty patients were enrolled in this study, broken into groups of five for each centre. 
Major eligibility criteria included patients aged between 18 and 69 years old, suffering from 
T1D for at least one year and using an insulin pump for at least six months, with HbA1c 
values <10%, continuous access to the Internet to download data from the monitoring 
website, cell phone service in case of necessity, and the presence of a companion who lives 
with the patient. Exclusion criteria were diabetic ketoacidosis or severe hypoglycaemia with 
seizure or loss of consciousness in the prior 12 months, hypoglycaemia unawareness, as well 
as medical conditions or laboratory abnormalities that could affect study participation. After 
the enrolment period, depending on the participant’s current experience with CGM use, 
patients spent a two-week period at home using both the study pump and the CGM. These 
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two weeks of SAP therapy at home were considered the baseline control period. After these 
two weeks, there was a training session to educate patients on DiAs usage, then two weeks of 
AP usage during the overnight period. In contrast to the previous study, dinner was not 
included in the testing and the patients were asked to start AP usage just before sleep. After 
these two weeks, the patients continued with two weeks of 24-hour system usage. The 
primary outcome was CGM sensor glucose values below target (<70 mg/dL, <3.9 mmol/L). 
During the periods of at-home CLC usage, remote safety monitoring was available to clinical 
staff.  
Results 
All participants completed the full four study weeks. Table 9 shows the characteristics 
of the patients in the study. 
Characteristic Study Population (n=30) 
Age (years) 44 (18-66) 
Sex (male) 17 (57%) 
BMI (Kg/m
2
) 25 (23-27) 
HbA1c (%) 7.3 (7.1-7.7) 
Diabetes duration (years) 19(13-28) 
Table 9: baseline characteristic of 30 patients. Data are described as median (25
th
-75
th
 quartile) or 
number (%) 
 
As shown in Table 10, all metrics regarding glucose control were improved in the 
night-time period. Time spent in hypoglycaemia (<70 mg/dl, <3.9 mmol//L) dropped from 
3.0% during baseline to 1.1% during overnight-only CLC (P < 0.001), while time in target 
(70-180 mg/dl, 3.9-10.0 mmol/L) increased from 61% to 75% (P < 0.001) and time spent 
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above 180 mg/dl (10 mmol/L) dropped from 37% to 24% (P < 0.001). Furthermore, the mean 
glucose concentration dropped from 163 to 150 mg/dL (P = 0.002) and glucose variability 
was improved by using AP, with a reduction of the median coefficient of variation (36% vs. 
30%, P < 0.001). 
  
Overnight period 
Metrics SAP therapy 
CLC 
overnight 
P value 
Glucose concentration, mg/dl 163±23 150±12 0.002 
Glucose standard deviation, mg/dl 61 (50-69) 47 (42-51) <0.001 
Time in target (70-180 mg/dl), % 61(53-73) 75 (69-80) <0.001 
Time below target (< 70 mg/dl), %  3.0 (1.1-6-3) 1.1 (0.2-1.6) <0.001 
Time above target (>180 mg/dl) % 37 (24-45) 24 (19-28) <0.001 
Table 10: results during overnight, expressed as mean ± standard deviation, or median (25
th
 -75
th
 
percentile).  
As shown in Table 11, metrics of glucose control in the 24-hour usage test improved 
during the day and night closed loop action compared with metrics recorded during SAP 
therapy. In particular, the time below 70 mg/dl (3.9 mmol/L) dropped from 4.1% to 1.7% (P 
< 0.001), time in target increased from 65% to 73% (P < 0.001), time above target decreased 
from 32% to 25% (P = 0.001), and the median coefficient of variation dropped from 38% to 
34% (P < 0.001). There was an insignificant difference in mean glucose concentration (157 
vs. 153 mg/dL, P = 0.14). Comparing the overnight and 24-hour AP usage on glycaemic 
control during day and night, a reduction in time spent in hypoglycaemia was observed when 
AP was used for 24 hours, with no differences in glucose concentration, time in target, and 
time above target (Table 12).  
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Day and night  
Metrics SAP therapy 24 hours CLC P value 
Glucose concentration, mg/dl 157 ± 18 153 ± 12 0.14 
Glucose standard deviation, mg/dl 61 (53-69) 51 (47-55) <0.001 
Time in target (70-180 mg/dl), % 65 (59-69) 73 (68-76) <0.001 
Time below target (< 70 mg/dl), %  4.1 (2.0-7.8) 1.7 (1.1-2.7) <0.001 
Time above target (>180 mg/dl) % 32 (25-36) 25(22-28) 0.001 
Table 11: results during day and night, expressed as mean ± standard deviation, or median (25
th
 -75
th
 
percentile).  
  
Day and night  
Metrics Overnight CLC 24 hours CLC P value 
Glucose concentration, mg/dl 149 ± 12 153 ± 12 0.06 
Glucose standard deviation, mg/dl 52 (48-58) 51 (47-55) 0.41 
Time in target (70-180 mg/dl), % 73 (65-78) 73 (68-76) 0.91 
Time below target (< 70 mg/dl), %  2.6 (1.6-3.6) 1.7 (1.1-2.7) <0.001 
Time above target (>180 mg/dl) % 24 (20-31)) 25(22-28) 0.26 
Table 12: results during day and night of 2 AP approaches, expressed as mean ± standard deviation, 
or median (25
th
 -75
th
 percentile).  
 
Comparing the overnight CLC system and 24 hour CLC usage in daytime control, 
results showed that median time <70 mg/dL, which was 3.2% during overnight-only CLC, 
was further reduced to 2.3% during 24/7 CLC (P < 0.001), but daytime mean glucose, median 
38 
 
time in target, 70–180 mg/dL (3.9-10 mmol/L), and median time above 180 mg/dL (10 
mmol/L) were not significantly different. 
There were no adverse events and no cases of severe hypoglycaemia or diabetic 
ketoacidosis during the trial. 
Conclusions 
This study also demonstrated that glucose control, using a different control algorithm, 
was significantly improved during both overnight-only and 24/7 CLC, compared with 
baseline SAP.  
As previously noted, overnight-only CLC provided a benefit in overall glycaemia, 
also in daytime. This effect is particularly evident during the morning, underling the fact that 
good glucose before breakfast improves glucose control during the whole morning period. 
During overnight CLC patients used DiAs during the day in OL mode. Some of the 
improvement could have been derived from more engaged patients, but this possibility is 
excluded by the results of the previous study in which the DiAs was switch off during the 
daytime.  
In any case, AP usage during the day is better than overnight CLC for the prevention 
of daytime hypoglycaemia. Using of an AP during the day doesn’t reduce hyperglycaemia 
because of the difficulty of the system in controlling meals and physical activity, which 
represent typical challenges of real life.  
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FEASIBILITY OF LONG TERM CLOSED-LOOP CONTROL: A MULTICENTER 6 
MONTH TRIAL OF 24/7 AUTOMATED INSULIN DELIVERY 
Methods 
As shown in Table 13, a subgroup of 14 patients from the previous study continued 
AP use 24 hours a day for another five months in free life conditions
77
. Patients were selected 
to continue the study based on clinician judgment. Patients were contacted weekly by phone 
and had monthly visits to download data.  
 
Characteristic Study Population (n=14) 
Age (years) 45 (34-51) 
Sex (male) 10 (71%) 
BMI (Kg/m
2
) 27 (25-29) 
HbA1c (%) 7.2 ± 0.6 
Diabetes duration (years) 27(17-34) 
Table 13: baseline characteristic of 14 patients. Data are described as median (25
th
-75
th
 quartile) or 
number (%) 
 
Baseline CGM data and HbA1c values were considered from two weeks of previous 
SAP study. It should be noted that since the HbA1c outcome measured at the end of the 
extension phase only reflects glucose control over the previous three months, CGM data were 
obtained from the last three months to be consistent with HbA1c outcomes. 
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Results 
Results confirmed data from the previous study; patients reached 77% of time in 
target using AP vs. 66% using SAP therapy at baseline, with a significant reduction in time 
spent in hypoglycaemia and hyperglycaemia. As shown in Table 14, time in hypoglycaemia 
was reduced from 4.1% to 1.3% (P < 0.001), while time above target dropped from 31% to 
22% (P = 0.01). Time spent in severe hypoglycaemic and hyperglycaemic values was also 
reduced, with a ten fold reduction of glucose values below 50 mg/dl (2.8 mmol/L), from 1% 
to 0.1%, and an important decrease of time above 250 mg/dl (13.9 mmol/L) from 6% to 3%. 
There was not a reduction of HbA1c during the six months of AP use (7.2% vs. 7.0%, P = 
0.23).  
 
Day and night  
Metrics Baseline CLC  P value 
Glucose concentration, mg/dl 154.8 ± 19.8 149.4 ± 10.8 0.25 
Time in target (70-180 mg/dl), % 66 (59-69) 77 (73-81) <0.001 
Time below target (< 70 mg/dl), %  4.1 (2.9-7.5) 1.3 (0.6-1.7) <0.001 
Time above target (>180 mg/dl) % 31 (23-38) 22 (19-27) 0.01 
Insulin used, IU/kg 0.59 ± 0.18 0.57 ± 0.22 NS 
Table 14: results during evening and night period, expressed as mean ± standard deviation, or median 
(25
th
 -75
th
 percentile).  
 
This study provided important data for evaluating the acceptance and efficacy of DiAs 
in a long-term study. DiAs use declined over the months, from 149 to 118 h/week of closed-
loop use, but HbA1c reduction was significantly correlated with system use.  
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Conclusions 
This represents the longest trial of AP use conducted in a real-life setting. The 
importance of this study is focused on the long-term acceptance and efficacy of AP use in the 
adult population. The impact of AP on daily life was satisfactory, as patients viewed the 
overnight system as beneficial, though some of them reported additional nuisance of the 
system on their relationship with their partners due to the alarm system and connectivity 
issues. Few users in fact affirmed that AP caused interruptions in their daily activities, and 
these were essentially at work, primarily related with the alarm system. Nevertheless, the 
alarms represent a safety requirement imposed by the regulatory board. During the last three 
months of the trial, CLC mode was used 70% of time, while an additional 8% of usage 
represents time when the DiAs was used in different modes of operation, for example in 
sensor only mode when the pump was not available or in OL mode when the sensor is not 
available, demonstrating the feasibility of this wearable AP model. Regarding connectivity 
issues, they could be solved by new technologies in sensors system (direct connection 
between CGM receiver and DiAs, without relay box) and by new AP model.  
Finally we have to remind that study was not designed to achieve statistically 
significant result, due to the small number of participants because it was just a pilot study. 
Nevertheless, long-term efficacy was confirmed, in term of hypoglycaemia reduction and 
partial HbA1c improvement, related to effective AP usage.  
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RANDOMIZED SUMMER CAMP CROSSOVER TRIAL IN 5- TO 9-YEAR-OLD 
CHILDREN: OUTPATIENT WEARABLE ARTIFICIAL PANCREAS IS FEASIBLE 
AND SAFE 
Good results obtained in adult populations allow the testing of the system in 
paediatricians
78
. Our American colleagues had tested DiAs in adolescents during summer 
camp with good result in efficacy, feasibility and acceptance
79
. Starting from such premises 
we decided to evaluate DiAS in paediatric population 5-9 year old, never studied before. This 
population has some peculiar characteristic such as an higher frequency of hypoglycaemic 
episodes
80
 than adult population, low insulin requirement, a difficult self management of 
therapy, intense but poorly predictable physical activity and poor dietetic adherence. 
Methods 
Algorithm used was the Padova-Pavia one, previously tested in silico in virtual 
paediatric population. Three months before this trial, we had a small pilot study to evaluate 
algorithm safety and AP feasibility in this particular population. This study was a multi-
centre Italian study, involving five paediatric centres in Italy (University of Verona, Milan, 
Turin, Naples, and Rome), coordinated by Padua University. Inclusion criteria were patients 
aged 5 to 9 years; with a diagnosis of T1D for at least 12 months; use of insulin pump and 
sensor; HbA1c < 10%, and attendance by at least one relative/caretaker. Exclusion criteria 
were diabetic ketoacidosis or severe hypoglycaemia within the last month, concomitant 
disease, as well as any medication or conditions that could influence metabolic control, 
compromise safety, or prevent study completion. 
The study was a randomized crossover study in a summer school setting. Patients 
were randomized into two groups that used AP or SAP for three days, with a 24-hour 
washout period between the two treatments (Fig. 8). The activities performed by the patients 
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were similar in the two periods and standardized every day, with static activities in the 
morning mimicking activities on school days and moderate physical activity in the afternoon. 
Carbohydrate levels were maintained at a stable level across different days.  
 
Figure 8: study design 
Differently from previous study, we used a new generation Dexcom receiver with 
blue tooth connection integrated in the receiver, which lead to “relay box” elimination.  
Results 
Table 15 shows the characteristics of the 30 patients who completed the study. 
Characteristic Study Population (n=30) 
Age (years) 7.6±1.2 
Sex (male) 19 (63%) 
BMI (Kg/m
2
) 16.9±2.1 
HbA1c (%) 7.3 ± 0.9 
Diabetes duration (years) 4.7±1.6 
Table 15: baseline characteristic of 30 patients. Data are described as mean ± standard deviation or 
number (%) 
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Data gathered during the night-time (Table 16) showed an important reduction of time 
spent in hypoglycaemia, from 2.2% (0.0–12.3) with SAP to 0.0% (0.0–2.2) with AP usage (P 
< 0.002), with no difference in time in target between the two arms. Results also showed an 
increase in mean glucose from 150 mg/dL with SAP usage to 173 mg/dL with AP usage (P = 
0.002).  
 
Overnight (00:00-07:30)  
Metrics SAP therapy CLC P value 
Glucose concentration, mg/dl 150 ± 39 173 ± 36 0.02 
Glucose standard deviation, mg/dl 44±14 47 ± 14 0.24 
Time in target (70-180 mg/dl), % 59.7±21.2 56.0 ±22.5 0.43 
Time below target (< 70 mg/dl), %  2.2 (0.0-12.3) 0.0 (0.0-2.2) 0.002 
Insulin used, IU/h 0.35±0.12 0.37±0.12 0.08 
Table 16: results during overnight, expressed as mean ± standard deviation, or median (25
th
 -75
th
 
percentile).  
 
During the 24-hour usage period (0000–2400), as shown in Table 17, the AP reduced 
more than three times the time-in hypoglycaemia, from 6.7% (2.3–11.5) with SAP to 2.0% 
(1.2–4.5), with the AP (P < 0.001). Unfortunately, hypoglycaemia reduction led to a decrease 
of time spent in target  (63.1% with SAP vs. 56.8% with the AP, P = 0.022) and an increase 
of mean glucose from 147 mg/dL with SAP vs. 169 mg/dL with the AP (P < 0.001). 
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Day and night  
Metrics SAP therapy CLC P value 
Glucose concentration, mg/dl 147 ± 23 169 ± 23 <0.001 
Glucose standard deviation, mg/dl 58±10 61 ± 11 0.17 
Time in target (70-180 mg/dl), % 63.1±11.0 56.8±13.5 0.02 
Time below target (< 70 mg/dl), %  6.7 (2.3-11.5) 2.0 (1.2-4.5) <0.001 
Insulin used, IU/h 0.35±0.12 0.26±0.09 <0.001 
Table 17: results during 24 hours, expressed as mean ± standard deviation, or median (25
th
 -75
th
 
percentile).  
 
No serious adverse events occurred, and the closed-loop mode remained fully 
operational for 97.0% (93.5–98.4) of the time. 
Conclusions 
This study demonstrated the feasibility of the AP model in the paediatric population. 
The improvement in hypoglycaemic values was encouraging, especially in this population 
characterized by a higher frequency of hypoglycaemic episodes than adults. The deterioration 
of time in target and worsening of median glycaemia is related to two elements. First, the 
characteristic of the population, under very good metabolic control, where mean HbA1c at 
the start was 7.3%, and characterized by a further reduction in glycaemia during the study 
period. Furthermore, during SAP therapy, parents were engaged in patients management 
therapy, in contrast to what happens normally at home, when parents work and children are at 
school.  
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Second, the AP algorithm was tuned prudent-by-design both for safety reasons and 
because this trial was the first with an adolescent-specific version of the MMPC algorithm, 
previously tested only in adults. 
At the end of the AP period, the patients’ parents completed an AP acceptance questionnaire 
in which 94.1% noted the intention for their child to use the AP in the long term and 91.3% 
thought that AP could improve glucose control. Encouragingly, 70.5% considered AP easy to 
use
81
.  
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DISCUSSION 
This thesis has demonstrated the efficacy of the wearable AP model in different 
populations and for different time periods. The safety and efficacy of this AP model to ensure 
glycaemic control, measured as time in range, and metabolic control, measured as HbA1c, 
was evaluated first during a night-time period, then over a 24-hour period, and finally for 
progressively longer periods.  
The DiAs was tested over 184,000 hours in over 300 patients with T1D, including 
data from other clinical centres, demonstrating its efficacy and feasibility in real life 
situations. Results demonstrated the superiority of AP over the actual gold standard Sensor 
Augmented Pump Therapy.  
The Experience of Other Groups with AP 
Other groups have demonstrated the efficacy of the AP model in different settings and 
populations. For example, Professor Hovorka’s group at Cambridge University developed 
another MMPC control algorithm that uses a different predictive control model as well as 
different insulin pumps and CGM systems
82
. They performed their outpatient and home 
studies by installing the control algorithm on a tablet or a mobile phone. In a randomized 
multi-centre (UK, Austria, and Germany) crossover trial, adult patients were randomized to 
start AP use for 24 hours/day, then use SAP therapy for 12 weeks or vice versa
83
. Results 
during the night and day usage demonstrated increased time in target (67.7% vs. 56.8%, P < 
0.001), reduced time above target of 180 mg/dl (10 mmol/L) from 38.9% to 29.2% (P < 
0.001), and reduced time below target of 70 mg/dl (3.9 mmol/L) from 3.0% to 2.9% (P = 
0.02). Mean glucose decreased from 168 to 157 mg/dl  (P < 0.001) and a reduction of glucose 
variability was also observed.  
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The same algorithm was then tested in 25 children and adolescents
83
 (mean age 12 
years old) during night-time usage and results were very encouraging. In fact, during day and 
night usage in young patients, results demonstrated improved time in target (61.2 vs. 51.6%, 
P < 0.001), reduced time above target (36.0 vs. 44.5%, P < 0.001), and reduced mean glucose 
levels (172 mg/dl vs. 182 mg/dl, P = 0.01). The study in adults demonstrated a reduction of 
0.3% of HbA1c, from 7.6% to 7.3% (P = 0.002).  
Also fuzzy logic algorithm, improved by a group from the University of Tel Aviv, 
Ljubljana, and Hannover, was tested in home-based patients in overnight periods for six 
weeks in 24 patients from 12 to 43 years old. Nocturnal hypoglycaemia, defined as glycaemia 
below 70 mg/dl (3.9 mmol/L), was reduced from 5.16% to 2.53% (P = 0.02), while time in 
tight target (70-140 mg/dl) increased from 36.3% to 47.4% (P = 0.003)
84
. 
A different approach was characterized by a bi-hormonal AP. In contrast to studies 
cited here that used only insulin to optimize glycaemic control, this prototype of the AP used 
two pumps: one for insulin and one for glucagon, the principal physiological hormone 
responsible for increase of glycaemia. The possibility of administering glucagon, which can 
mitigate or prevent hypoglycaemia, allows a more aggressive insulin infusion to reach a 
tighter control
85
.  
This AP model was also evaluated in a randomized crossover trial, in which a dual 
hormone AP was compared with usual patient therapy (SAP or continuous subcutaneous 
insulin infusion) for 11 days. Results demonstrated the safety of the system over 24 hours 
with improved glucose variability, as well as a reduction of mean glucose (7.8 vs. 9 mmol/l, P 
< 0.0001) time in hypoglycaemia (1.9% vs. 0.6%, P < 0.0001), and time in hyperglycaemia 
(19.8% vs. 33.6%, P < 0.0001)
86
. This model was also tested in paediatric patients, from 6 to 
11 years old, in a summer camp. Nineteen patients with a mean age of 9.8 years old were 
randomized to use AP or an insulin pump for five days, then, after a three-day wash-out, they 
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used the other treatment
87
. The bi-hormonal AP led to a reduction of mean glucose (137 vs. 
167 mg/dl, 7.6 vs. 9.3 mmol/L, P = 0.00037), time below 3.3 mmol/L (1.2% vs. 2.8%, p < 
0.0001), and time above 180 mg/dl (10 mmol/L) (16.5% vs. 36.3%, P < 0.0001). Time in 
target increased from 57.6% to 80.6% (P < 0.0001). Bi-hormonal CLC has some critical 
points, too. First, it requires the use of two pumps, one for insulin and one for glucagon, in 
addition to CGM, which is not always well tolerated by patients. Furthermore, it is necessary 
to find a glucagon formulation that is stable for a sufficient time and to assess the 
effectiveness of repeated glucagon administration. 
The AP was also tested in different situations. For example, Hovorka and his 
colleagues evaluated CLC efficacy in T1D pregnant women, demonstrating the safety of the 
system in this critical period
88
. Sixteen pregnant women (from 18 to 45 years old, between 8 
and 24 weeks of gestation) were enrolled in a randomized crossover trial that compared four 
weeks of overnight AP use and SAP therapy. Results demonstrated the superiority of CLC in 
glycaemic values, reducing time in hypo- and hyperglycaemia. At the end of the randomized 
period, patients could continue to use CLC for 24-hour periods and during labour and 
delivery with good results and an absence of adverse events.  
AP was also tested in critically ill inpatients, randomized to receive glucose control 
through the AP or through local protocol of endovenus insulin infusion. Even in these critical 
patients, CLC was superior to classical therapy
89
.  
Another example of CLC superiority was demonstrated in adolescents who forget or 
underdose bolus administration at meals. This happens frequently in young diabetic patients 
and leads to a worsening of metabolic control. Even though the AP model needs meal 
announcements (CHO intake or meal size) to administer a meal bolus and avoid postprandial 
hyperglycaemia, having a meal without announcing it and obviously without bolus is better 
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controlled using AP than with usual therapy, due to an automatic increase of basal rate or 
automatic bolus when glycaemia arises
90
.  
Other studies have compared different algorithms. For example, a comparison 
between PID and MPC controllers during 27-hour supervised sessions was published in 2016. 
Results showed that MPC demonstrated better glycaemic control, with a lower mean 
glycaemia and more time spent in target
91
. 
A bi-hormonal pancreas was also compared to insulin CLC using an MPC controller 
in 20 adults and 10 adolescents in a randomized crossover trial that included 24-hour access 
to a clinical research centre, meals, and physical activity. This bi-hormonal system 
demonstrated a further reduction of time spent in hypoglycaemia compared with the insulin-
alone AP with no differences in mean sensor glucose levels
92
. 
Critical points 
Some critical points remain, for example, the necessity to announce meals to inject a 
bolus to avoid postprandial hyperglycaemia or to manage physical activity. Controlling 
postprandial glucose excursions is important for achieving a healthy HbA1c target
93-94
. The 
main important determinant in controlling postprandial glycaemic peaks is carbohydrate 
content, which patients usually have to calculate to determine the amount of insulin bolus, 
based on a carbohydrates-to-insulin ratio. It’s not always easy for patients to calculate the 
amount of carbohydrates before a meal and related errors can deteriorate postprandial 
glycaemic control
95
. In addition to evaluating the amount of carbohydrates, patients must 
evaluate their food’s glycaemic index96-97, defined as the speed with which food is absorbed, 
which determines the time of glycaemic peaks. Obviously, other factors like physical activity 
and the ingestion of protein, fat, and fibres can influence the pace of carbohydrate 
absorption
98-99
. Rapid-acting insulin analogues used need 15 minutes to be absorbed from 
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subcutaneous tissue to blood and perform their actions, with a peak action between one and 
two hours, while glucose absorption after meals is more rapid
100-101
.  
Meal announcement is a critical point related to slow insulin action and to the 
mismatch between insulin and food absorption. Recently, a faster insulin that could minimise 
the delay in insulin absorption and improve AP efficacy has been introduced in therapy
102-104
. 
Another technique to accelerate insulin absorption is to combine insulin with hyaluronidase, 
an enzyme that increases the passage of insulin from subcutaneous tissue to blood
105
. 
Pramlintide administration before a meal can also delay gastric emptying, leading to better 
postprandial control
106
. Some studies have evaluated CLC with pramlintide administration 
demonstrating a postprandial peak reduction
107-108
. In the same way, GLP-1 analogues could 
also be a promising alternative. These new drugs, often used in type 2 diabetes therapy, lead 
to delayed gastric emptying and a suppression in glucagon release. The addition of liraglutide 
(a GLP-1 analogue) to CLC improved overall glucose control and, in particular, postprandial 
control
109
. 
Until now, most AP models are hybrid closed loop systems because of the need for 
meal announcements, inserting CHO intake or meal size
110
 to help the algorithm to control 
postprandial glucose peaks. A fully-automated CLC, with no need to insert meal or physical 
activity, has also been tested, but in a small number of subjects in an inpatient setting. 
Optimization of a fully-automated CLC may be possible with new faster insulin or new 
approaches. This solution could be more appreciated by patients, reducing the risk of errors in 
CHO calculation
111-113
.   
Another critical point to note about CLC is that the quick variation in glucose levels 
during physical activity means that such activity is not always well evaluated by sensors, and 
such activity must be accurately anticipated or prevented to obtain a complete automation of 
the system. Different approaches have been evaluated. For example, a heart rate frequency 
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sensor
114
 or accelerometer, to estimate physical activity, inserted in algorithm control could 
provide other data to prevent hypoglycaemia related to sport, as demonstrated in recent trial 
in adolescents where heart rate was inserted in algorithm. During physical activity, the heart 
rate increases, providing important information to the system to optimize control. In fact, a 
reduction of time spent in hypoglycaemia compared to the classical closed loop system was 
observed. 
Another critical point that impacts the efficacy of AP is the accuracy of the sensors. In 
recent years, CGM accuracy has rapidly improved, and some sensors have been approved by 
FDA as a non-adjunctive system
115
, replacing the glucometer in diabetes-related patient 
choices. Furthermore, CGMS performance can be influenced by calibration or signalling 
errors
116-117
. Patient education is critical to avoiding calibration errors and identifying sensor 
inaccuracy
118
, even if the AP systems have algorithms to determine sensor inaccuracy and 
often use also glycaemic capillary values to improve control.  
The control algorithm could also be improved to obtain better control during the day, 
maybe developing adaptive algorithm with daily automatic adaption of patients’ parameters 
to optimize glycaemic control, as tested in a pilot study by our group
119
.  
Also the “platform” could be improved, in particular regarding connections between 
different devices. For example, Dexcom G4 evolution has Bluetooth connection integrated in 
the receiver (as used in paediatricians trial). Dexcom G5 (new Dexcom generation) could 
send data directly from transmitter to AP, with no receiver or relay box requirement, solving 
some connection problems.  
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CONCLUSIONS 
 
Important progress has been made in the last five years leading to more positive 
prospects in the future therapy of T1D patients that have been engaged all their life in 
controlling glucose levels and avoiding acute and chronic disease complications.  
Our data and results from other groups involved in AP development demonstrated the 
feasibility and efficacy of this technology.  
It has been demonstrated that glucose variability is related with complications 
development in type 1 and type 2 diabetic patients
120
. Several studies demonstrated a 
reduction in glucose variability using AP, probably leading to a less incidence of 
complications. Obviously long term studies are necessary to confirm this assumption.  
Furthermore also acceptance of the system by patients is encouraging, even if remains 
problems with connection between devices and alarms are not always well tolerated.  
Some months ago, the FDA approved the first Hybrid CLC, the Medtronic one, which 
uses a PID algorithm, demonstrating the validity of this new therapeutic approach. 
Obviously, more data are necessary to translate this technology from research field to 
clinical application. For example studies of several months in a large cohort of patients to 
evaluate long-term efficacy, or in not selected patients, for example in worse controlled or 
less compliant subjects. More studies are necessary in particular populations, as type 1 
diabetic pregnant women or very young diabetic patients.    
 Furthermore the cost-effectiveness of closed-loop systems is to be determined to 
support access and reimbursement of this technology. 
Prolonged multinational closed-loop clinical trials, enrolling hundreds of patients are 
currently underway or in preparation, to definitively confirm efficacy of Artificial Pancreas 
for type 1 diabetic patients.  
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